Bio-Techne (NASDAQ: TECH) insider transactions
In the twelve months to 10 November 2026, executives and directors of Bio-Techne reported 2 open-market sales of 8,612 shares ($437,187) and 0 open-market purchases, by 1 person, according to the Form 4 filings they submitted to the SEC.
Latest transactions
| Date | Insider | Role | Transaction | Shares | Price | Held after | Filing |
|---|---|---|---|---|---|---|---|
| 1 November 2026 | Hippel James | CFO | Option exercise | +11,545 | — | 181,816 | Form 4 |
| 1 November 2026 | Hippel James | CFO | Shares withheld for tax | −5,096 | $72.66 | 176,720 | Form 4 |
| 1 November 2026 | Kelderman Kim | Chief Executive Officer | Shares withheld for tax | −2,385 | $72.66 | 80,509 | Form 4 |
| 29 October 2026 | Baumgartner Robert V | Director | Grant or award | +2,750 | — | 59,634 | Form 4 |
| 29 October 2026 | Bushman Julie L | Director | Grant or award | +2,750 | — | 11,525 | Form 4 |
| 29 October 2026 | Higgins John L | Director | Grant or award | +2,750 | — | 80,004 | Form 4 |
| 29 October 2026 | Keegan Joseph D | Director | Grant or award | +2,750 | — | 18,161 | Form 4 |
| 29 October 2026 | Herr Amy E. | Director | Grant or award | +2,750 | — | 5,430 | Form 4 |
| 29 October 2026 | Klimovsky Judith V. | Director | Grant or award | +2,750 | — | 6,532 | Form 4 |
| 29 October 2026 | Seth Alpna | Director | Grant or award | +2,750 | — | 18,161 | Form 4 |
| 29 October 2026 | Vessey Rupert | Director | Grant or award | +2,750 | — | 13,737 | Form 4 |
| 28 September 2026 | Higgins John L | Director | Option exercise | +15,940 | — | 82,816 | Form 4 |
| 28 September 2026 | Higgins John L | Director | Shares withheld for tax | −5,562 | $72.51 | 77,254 | Form 4 |
| 22 September 2026 | Baumgartner Robert V | Director | Option exercise | +15,940 | — | 62,443 | Form 4 |
| 22 September 2026 | Baumgartner Robert V | Director | Shares withheld for tax | −5,559 | $72.55 | 56,884 | Form 4 |
| 15 August 2026 | Herr Amy E. | Director | Option exercise | +589 | — | 789 | Form 4 |
| 15 August 2026 | Herr Amy E. | Director | Shares withheld for tax | −213 | $72.40 | 576 | Form 4 |
| 15 August 2026 | Crouse Steven C. | President - Diag & Spatial Bi | Option exercise | +5,423 | — | 12,184 | Form 4 |
| 15 August 2026 | Crouse Steven C. | President - Diag & Spatial Bi | Shares withheld for tax | −1,947 | $72.40 | 10,237 | Form 4 |
| 15 August 2026 | Bohnen Shane | SVP - General Counsel | Option exercise | +4,350 | — | 11,703 | Form 4 |
Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.
How to read the table
Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.
Where each row comes from
From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Bio-Techne page; the method, in data sources.
Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.